Apple stock hits all-time high, reaching 311.18 USD
Apple Inc. stock has hit an all-time high of $311.18, marking a 59.11% surge over the last year and boosting its market capitalization to $4.57 trillion. The company's strong performance is attributed to robust product demand, strategic innovations, and revenue growth. While analysts have revised earnings upwards and the company boasts a perfect Piotroski Score, InvestingPro's Fair Value analysis suggests the stock is currently overvalued.
Mizuho raises Ventas stock price target to $98 on higher estimates
Mizuho has increased its price target for Ventas Inc. (NYSE:VTR) to $98 from $94, maintaining an Outperform rating, due to higher funds from operations (FFO) and adjusted funds from operations (AFFO) estimates for 2026 and 2027. The updated price target implies an 11% upside from current levels, although InvestingPro analysis suggests the stock might be overvalued. This follows Ventas' strong first-quarter 2026 results which surpassed Wall Street expectations, along with an increased ATM Sales Agreement and a declared quarterly dividend.
Mizuho raises Ventas stock price target to $98 on higher estimates
Mizuho has increased its price target for Ventas Inc. (NYSE:VTR) to $98 from $94, maintaining an Outperform rating due to higher estimates for 2026 and 2027 funds from operations. This revision follows strong first-quarter results where Ventas surpassed Wall Street expectations for both EPS and revenue, and updated its ATM Sales Agreement to $3 billion. The new target implies an 11% upside from current levels for the healthcare REIT.
Mizuho raises Ventas stock price target to $98 on higher estimates
Mizuho raised its price target on Ventas Inc. (NYSE:VTR) to $98 from $94, maintaining an Outperform rating due to higher funds from operations (FFO) and adjusted FFO (AFFO) estimates for 2026 and 2027. The updated target implies an 11% upside from current levels, though InvestingPro analysis suggests the stock might be overvalued. This follows Ventas' strong first-quarter 2026 earnings, which surpassed Wall Street expectations for both EPS and revenue, and an increase in its ATM Sales Agreement to $3 billion.
Mizuho Adjusts Price Target on Ventas to $98 From $94, Maintains Outperform Rating
Mizuho has increased its price target for Ventas Inc. (NYSE: VTR) to $98 from $94, while reiterating an "Outperform" rating on the stock. This adjustment reflects a positive outlook from the analyst firm regarding the healthcare real estate investment trust. The article also lists recent analyst adjustments and company news for Ventas.
Ventas Inc. stock (US92276F1003): ATM expansion and SHOP growth keep healthcare REIT in focus
Ventas Inc. (VTR) is highlighted for expanding its at-the-market (ATM) equity program and demonstrating strong growth in its senior housing operating portfolio (SHOP). The healthcare REIT's normalized FFO per share increased 9% in Q1 2026, driven by SHOP performance and contributions from life science and medical office assets. Analysts offer a "moderate buy" consensus with a 12-month price target above current trading levels, viewing the ATM expansion as a flexible way to fund growth and manage its balance sheet, despite potential dilution concerns.
Ventas Is Maintained at Sector Perform by Scotiabank
Scotiabank has reiterated its "Sector Perform" rating on Ventas (NYSE: VTR) stock. The analyst firm has also set a price target of $46.00 for the healthcare real estate investment trust.
Scotiabank Adjusts Price Target on Ventas to $95 From $93, Maintains Sector Perform Rating
Scotiabank has increased its price target for Ventas (VTR) shares to $95 from $93, while maintaining a "Sector Perform" rating on the stock. This adjustment reflects the bank's updated outlook on the healthcare and medical-residential facilities company. Other financial institutions like Goldman Sachs, Jefferies, JPMorgan, BMO Capital, UBS, RBC, Argus, and Evercore ISI have also recently adjusted their price targets for Ventas, indicating active analyst coverage of the company.
Aew Capital Management L P Sells 87,710 Shares of Ventas, Inc. $VTR
Aew Capital Management L P significantly reduced its stake in Ventas, Inc. (NYSE:VTR) by selling 87,710 shares, decreasing its holdings by 79.3% in the fourth quarter. Other institutional investors also made purchases, while analysts maintain a "Moderate Buy" rating with an average price target of $94.63. The company also announced a quarterly dividend of $0.52 per share and reported Q1 earnings that missed consensus estimates.
Ventas stock (US92276F1003): ATM expansion puts capital flexibility in focus
Ventas, a healthcare REIT, has expanded its at-the-market (ATM) equity program, which grants it increased flexibility to issue shares for managing capital needs and funding portfolio growth. This move is significant given the current market's focus on funding costs and acquisition capacity for REITs. Analysts currently hold a "moderate buy" consensus for Ventas, with an average 12-month price target above its recent trading price, indicating potential for the stock to increase.
GRS Advisors Opens $49 Million Broadstone Net Lease Position, According to Recent SEC Filing
GRS Advisors initiated a new position in Broadstone Net Lease (BNL) during the first quarter of 2026, acquiring over 2.6 million shares valued at approximately $48.65 million. This transaction makes BNL almost 5% of GRS Advisors' reportable AUM. The article also provides an overview of Broadstone Net Lease, highlighting its focus on diversified single-tenant commercial properties and its strategy for predictable cash flows.
GRS Advisors Opens $49 Million Broadstone Net Lease Position, According to Recent SEC Filing
GRS Advisors, LLC initiated a new position in Broadstone Net Lease (BNL) during the first quarter of 2026, acquiring 2,663,028 shares valued at an estimated $50.13 million. This new position represents 4.81% of GRS Advisors' reportable assets under management. Broadstone Net Lease is a diversified real estate investment trust focused on single-tenant commercial properties and targets stable, creditworthy lessees.
GRS Advisors Opens $49 Million Broadstone Net Lease Position, According to Recent SEC Filing
GRS Advisors, LLC initiated a new position in Broadstone Net Lease (BNL) by acquiring over 2.6 million shares valued at approximately $49 million, as disclosed in a Q1 2026 SEC filing. This new holding represents 4.81% of GRS Advisors' reportable assets under management. The article details Broadstone's business model as a diversified REIT focused on long-term net leases, emphasizing that future investor returns will depend on its ability to translate stable rent streams and strategic acquisitions into per-share AFFO growth.
Ventas Expands ATM Program to Bolster Capital Flexibility
Ventas (VTR) has expanded its at-the-market (ATM) equity program to allow for up to $3 billion in new common stock issuance, enhancing its financial flexibility. This move follows a leadership transition and shareholder approval of director nominees and executive pay. An AI analyst rates VTR as Neutral due to strong earnings and technical momentum, balanced by valuation concerns and balance sheet leverage.
Ventas stock (US92276F1003): Healthcare REIT outlines growth strategy after recent quarterly results
Ventas, a major US healthcare REIT, has updated investors on its latest quarterly figures and portfolio strategy, highlighting senior housing and medical office assets as key revenue drivers for the years ahead. The company's strategy focuses on owning and managing real estate for healthcare and senior living sectors, primarily in the US and Canada, with a mix of triple-net leases and senior housing operating portfolios. Ventas aims to balance growth opportunities with capital discipline, emphasizing portfolio quality, partnerships, and favorable market characteristics, while being influenced by demographic trends, healthcare policy, and capital market conditions.
Ventas’s SWOT analysis: healthcare REIT stock faces demographic tailwinds
Ventas, Inc. (NYSE:VTR), a healthcare real estate investment trust, is positioned to benefit from the aging global population by specializing in senior housing and medical office buildings. Analysts have expressed confidence in Ventas, raising price targets and identifying it as a top stock due to the resilient demand in the healthcare real estate sector. The article includes a SWOT analysis, highlighting strengths like its focused portfolio and demographic tailwinds, weaknesses such as dependence on healthcare reimbursement, opportunities including strategic acquisitions, and threats like regulatory changes and competition.
North Dakota State Investment Board Purchases New Holdings in Ventas, Inc. $VTR
The North Dakota State Investment Board has acquired a new stake in Ventas, Inc. (NYSE:VTR), purchasing 15,534 shares valued at approximately $1.2 million during the fourth quarter. This move aligns with other institutional investors like Vanguard, JPMorgan Chase, and State Street who also increased their holdings in the healthcare REIT. Analysts maintain a "Moderate Buy" consensus for Ventas, with an average price target of $94.63, supported by its recent revenue beat although EPS missed expectations.
Welltower stock (US95040Q1040): REIT extends health-care push as shares trade near record levels
Welltower Inc. (US95040Q1040) is gaining renewed investor attention as its stock trades near record levels at $216.22 on May 20, 2026. The REIT specializes in senior housing and health-care properties, offering exposure to the aging population demographic in the US and Canada. Its business model, focused on lease income and property operations, makes its performance sensitive to occupancy rates, rent growth, and interest-rate expectations.
Goldman Sachs Maintains Ventas Inc(VTR.US) With Buy Rating, Raises Target Price to $110
Goldman Sachs analyst Julien Blouin has reiterated a "Buy" rating for Ventas Inc (VTR.US) and increased the target price from $100 to $110. According to TipRanks, the analyst has a 42.4% success rate and an average return of 1.4% over the past year. This rating is based on an independent third-party analysis by TipRanks, which evaluates analysts' performance.
Goldman Sachs Adjusts Price Target on Ventas to $110 From $100, Maintains Buy Rating
Goldman Sachs has increased its price target for Ventas (VTR) to $110 from $100, while reaffirming a Buy rating on the stock. This adjustment reflects a positive outlook for the specialized REIT, which primarily owns and manages healthcare and medical-residential facilities across the United States, Canada, and the United Kingdom. The company recently declared a quarterly dividend of $0.52 per share payable in July.
Ventas stock (US92276F1003): Q1 results highlight senior housing growth
Ventas Inc. reported strong Q1 2026 results, with normalized FFO per share up 9% year over year and senior housing operating portfolio (SHOP) being a key growth driver. The healthcare REIT's performance, marked by a 15% increase in same-store cash NOI from SHOP, makes it relevant for investors interested in real estate income tied to the aging population. The article emphasizes that Ventas's business model, focused on senior housing, medical offices, and healthcare properties, distinguishes it from traditional REITs and positions it to benefit from domestic healthcare utilization and demographic trends.
Here is Why Ventas (VTR) is One of the Best Large Cap Stocks to Buy Under $100
Ventas Inc. (VTR) is highlighted as a top large-cap stock under $100, following strong Q1 2026 financial results driven by significant organic growth in its senior housing operating portfolio. The company reported increased net income, Normalized FFO, and Net Operating Income, leading to raised full-year guidance and strengthened financial flexibility. Ventas, a healthcare-focused REIT, owns a diverse portfolio of properties across North America and the UK.
AlphaCore Capital LLC Invests $1.26 Million in Ventas, Inc. $VTR
AlphaCore Capital LLC has invested $1.26 million in Ventas, Inc. by purchasing 16,317 shares, opening a new position in the company. Institutional investors collectively own 94.18% of Ventas, with several other major firms also increasing their stakes. Ventas reported Q4 revenue of $1.65 billion, exceeding expectations, though its EPS of $0.11 slightly missed estimates.
Ventas Expands Equity Program And Confirms Governance Stability Might Change The Case For Investing In Ventas (VTR)
Ventas, Inc. recently expanded its at-the-market equity program to allow up to US$3.00 billion in common stock issuances and re-elected all 12 directors. This move provides the company with greater capital-raising flexibility and ensures continuity in corporate oversight, which could impact its investment narrative centered on healthcare real estate growth. Investors should monitor how Ventas balances cash dividends, equity issuance, and acquisition activity, especially given the ongoing risks in its Senior Housing Operating Portfolio.
A Look At Alexandria Real Estate Equities (ARE) Valuation After Earnings Beat And Sector Downgrades
Alexandria Real Estate Equities (ARE) recently held its shareholder meeting, confirming board elections and executive pay approvals, with earnings surpassing forecasts despite revenue and sector downgrades. The stock has seen a 7.5% decline in the past month and a 34.2% fall in the 1-year total shareholder return, reflecting cooling sentiment. Despite this, the company is considered approximately 48.9% undervalued with a fair value of $88 compared to its last close of $44.97, based on NAV per share and accounting for sector risks like declining rents and property impairments.
Ventas Expands Equity Program And Confirms Governance Stability Might Change The Case For Investing In Ventas (VTR)
Ventas, Inc. recently expanded its at-the-market equity program to US$3.00 billion and re-elected all directors, highlighting a focus on capital-raising flexibility and continuous corporate oversight. This move, alongside the affirmation of a quarterly dividend, impacts Ventas's investment narrative centered around healthcare real estate growth, particularly in balancing equity issuance and acquisition activities with senior housing performance. Investors should consider how these financial strategies and ongoing risks might shape future returns for the company.
Ventas Inc. stock (US92276F1003): Latest company update and what investors are watching
Ventas Inc. (VTR) is a healthcare real estate investment trust (REIT) observed by investors for its exposure to senior housing, medical office, and other healthcare properties. The company's performance is influenced by occupancy rates, interest rates, and reimbursement trends, making it an income-oriented investment. It is also sensitive to changes in borrowing conditions and real estate valuations, with its core business model relying on rental income and property-related cash flow from its healthcare-related real estate portfolio.
Senior Housing Prop stock (US81721M1099): REIT pivots to Diversified Healthcare name amid portfolio challenges
Senior Housing Prop, now known as Diversified Healthcare Trust, is navigating a difficult healthcare real estate market by reshaping its portfolio strategy. The REIT is focusing on senior housing, medical office, and life science properties in the US, balancing rising interest rates and operating costs with improving occupancy and demand for outpatient medical space. Management's efforts to stabilize cash flows and adapt its balance sheet are key to its future performance.
Ventas Expands ATM Program to Bolster Capital Flexibility
Ventas (VTR) has expanded its at-the-market equity program to issue up to $3 billion in new common stock, significantly enhancing its financial flexibility and capital-raising potential. This move follows recent corporate actions, including a leadership transition and the re-election of its board. Analysts currently rate VTR as a Buy with a $100 price target, while TipRanks' AI Analyst labels it Neutral due to strong operational performance tempered by valuation concerns.
ANTIPODES PARTNERS Ltd Sells 243,423 Shares of Ventas, Inc. $VTR
ANTIPODES PARTNERS Ltd significantly reduced its stake in Ventas, Inc. (NYSE:VTR) by selling 243,423 shares in the fourth quarter, decreasing its holding by 22.1% to 856,972 shares valued at $66.3 million. Despite Ventas missing EPS estimates slightly, its revenue beat expectations and increased by 22%, and analysts largely maintain a "Moderate Buy" rating with a consensus price target of $94. The company also announced a quarterly dividend of $0.52 per share and provided FY 2026 EPS guidance.
Ventas (NYSE: VTR) director sells 1,152 shares, receives 2,047 RSUs
Ventas, Inc. director Walter C. Rakowich recently engaged in two transactions involving the company's common stock. He acquired 2,047 restricted stock units (RSUs) on May 13, 2026, which vest on the earlier of one year or the company's 2027 annual stockholders' meeting. The following day, May 14, 2026, Rakowich sold 1,152 shares at a weighted average price of approximately $90.20 per share under a pre-established Rule 10b5-1 trading plan.
Ventas director Rakowich sells $103,915 in company stock
Walter C. Rakowich, a director at Ventas, Inc. (NYSE: VTR), recently sold 1,152 shares of company stock for approximately $103,915, executed under a Rule 10b5-1 trading plan. This transaction followed his acquisition of 2,047 restricted stock units valued at $184,946. Ventas, a healthcare REIT, has a market capitalization of $44.05 billion and has shown a 38.6% return over the past year, although InvestingPro suggests it is currently overvalued.
Ventas director Rakowich sells $103,915 in company stock
Ventas director Walter C. Rakowich sold 1,152 shares of Ventas common stock for approximately $103,915 on May 14, 2026, as part of a Rule 10b5-1 trading plan. This transaction occurred after he acquired 2,047 restricted stock units the previous day, valued at $184,946. Despite the sale, Rakowich still holds 28,349 shares, and Ventas recently surpassed Q1 2026 earnings expectations, leading to an increased price target from Evercore ISI.
Ventas director Rakowich sells $103,915 in company stock By Investing.com
Walter C. Rakowich, a director at Ventas, Inc., sold 1,152 shares of company stock for approximately $103,915 on May 14, 2026, as part of a Rule 10b5-1 trading plan. This sale occurred near the stock's 52-week high, shortly after he acquired 2,047 restricted stock units valued at $184,946. Despite the "overvalued" assessment by InvestingPro, Ventas recently reported strong Q1 2026 financial results, surpassing analyst expectations for EPS and revenue, leading to an upgraded price target from Evercore ISI.
Insider Selling: Ventas (NYSE:VTR) Director Sells 1,152 Shares of Stock
Ventas (NYSE:VTR) Director Walter Rakowich sold 1,152 shares of the company's stock on May 14th for approximately $103,910 under a pre-arranged trading plan, reducing his stake by 3.9%. Following the sale, Rakowich retains 28,349 shares valued around $2.5 million. The stock price was down 2.8% to $87.47 on Friday, near its 52-week high, and the company recently reported Q1 earnings that missed estimates but beat on revenue.
Ventas updates ATM sales agreement and announces annual meeting results
Ventas, Inc. updated its At-The-Market Sales Agreement, increasing the potential stock issuance to $3 billion, and announced the results of its 2026 Annual Meeting of Stockholders. Shareholders re-elected all 12 director nominees, approved executive compensation, and ratified KPMG LLP as the independent auditor. The company also disclosed a separation agreement with Peter J. Bulgarelli, related to his retirement.
Ventas's Peter J. Bulgarelli to Receive Prorated 2026 Bonus upon Retirement
Ventas has agreed to provide Peter J. Bulgarelli with a prorated 2026 bonus as part of a separation agreement, following his retirement on May 1, 2026. Bulgarelli served as Executive Vice President, Outpatient Medical & Research, and President and CEO of Lillibridge Healthcare Services. This information was disclosed in an SEC filing by Ventas, Inc. [VTR].
Ventas (VTR) director Sean P. Nolan receives 2,047 restricted stock units grant
Ventas (VTR) director Sean P. Nolan was granted 2,047 restricted stock units (RSUs) at a reference price of $90.35 per share, valued at approximately $185,000. These RSUs vest on the earlier of one year from the grant date or the company's 2027 Annual Meeting of Stockholders. Following this transaction, Nolan directly holds 26,181 shares of Ventas common stock.
Ventas Inc - Enters Amendment No. 3 To ATM Sales Agreement On May 15, 2026 - SEC Filing
Ventas Inc. has announced it entered Amendment No. 3 to its ATM Sales Agreement on May 15, 2026. This information was disclosed in an SEC filing and reported by Reuters. The announcement is a financial update regarding the real estate investment trust company.
Ventas (VTR) director Matthew Lustig receives 2,047 restricted stock units grant
Matthew J. Lustig, a director at Ventas, Inc. (VTR), was granted 2,047 restricted stock units (RSUs) valued at $90.35 per share. This equity award, part of the 2022 Incentive Plan, is tied to ongoing board service and will vest on the earlier of one year from the grant date or the company's 2027 Annual Meeting of Stockholders. Following this grant, Lustig directly holds 95,005.712 shares of Ventas common stock.
Director Sumit Roy receives 2,047-share equity award at Ventas (NYSE: VTR)
Ventas, Inc. director Sumit Roy was granted 2,047 shares of common stock as restricted stock units under the company's 2022 Incentive Plan. The award, valued at $90.35 per share, will vest on the earlier of one year from the grant date or the 2027 Annual Meeting of Stockholders. Following this grant, Roy's direct holdings in Ventas common stock amount to 24,404.224 shares.
Ventas, Inc. (NYSE: VTR) director receives 2,047-share stock award
Ventas, Inc. director Maurice S. Smith was granted 2,047 restricted stock units (RSUs) as part of his director compensation under the company's 2022 Incentive Plan. These RSUs, valued at $90.35 per share on the grant date, will vest on the earlier of one year from the grant date or the 2027 Annual Meeting of Stockholders. Following this award, Smith directly holds a total of 30,722.671 shares of Ventas common stock.
Ventas (VTR) director Theodore Bigman receives 2,047 restricted stock units grant
Ventas (VTR) director Theodore Bigman was granted 2,047 restricted stock units (RSUs) as an equity award under the company's 2022 Incentive Plan. The grant, valued at $90.35 per share, will vest on the earlier of one year from the grant date or Ventas's 2027 Annual Meeting of Stockholders. Following this award, Bigman directly holds 10,640 shares of Ventas common stock.
CAVA Group Crossed $1 Billion in Revenue With a 168% Upside Case Still on the Table
CAVA Group, a Mediterranean fast-casual restaurant chain, surpassed $1 billion in annual revenue in 2025, expanding to 439 locations. Despite strong unit economics and growth, the stock faces valuation concerns, especially after an Argus Research downgrade, leading to a divided Street analyst consensus on its price target. A TIKR model suggests a 168% upside to $204 by 2030, contingent on sustained same-restaurant sales growth and operational execution amidst new market entries and menu additions.
Ventas Stock Has Surged 45% in 12 Months. Does the Valuation Still Hold Up in 2026?
Ventas, Inc. (VTR) stock has surged 45% over the past year due to strong demographic tailwinds in senior housing and healthcare real estate. Despite a robust Q1 2026 performance and raised full-year guidance, a valuation model projects only modest annualized returns of 2.8% through December 2028. This suggests that much of the potential upside from the company's favorable market position may already be priced into the stock following its recent rally.
Ventas Inc. stock (US92276F1003): REIT deal activity keeps the US senior housing story in focus
Ventas Inc. is drawing attention due to its substantial investment activity in the U.S. senior housing sector, with $5.7 billion invested over the past 18 months. This healthcare REIT's focus on senior housing, medical office buildings, and other healthcare real estate positions it as an income-oriented property stock linked to demographics and care delivery needs. While the company's business model is straightforward, its future performance hinges on property performance, capital deployment, and the broader interest rate environment, making it a significant stock for U.S. investors seeking real asset exposure with a healthcare angle.
National Healthcare Properties reports SHOP momentum continues
National Healthcare Properties reported "exceptional" first-quarter results for its senior housing operating platform (SHOP), driven by improvements in occupancy, rate, and margin expansions. The company's CEO, Michael Anderson, highlighted significant senior housing investments and its recent initial public offering, which raised approximately $531 million. This reorientation towards senior housing marks a major milestone for the company, further emphasizing its commitment to this sector.
[144] Ventas, Inc. SEC Filing
This article details a Form 144 SEC filing by Ventas, Inc. (VTR) concerning a proposed sale of securities. The filing indicates a sale of 1152 common shares with an aggregate market value of $103,864.32, acquired through an RSU grant. The filing is categorized as neutral in both impact and sentiment.
Earnings call transcript: National Healthcare Properties Q1 2026 shows strong growth
National Healthcare Properties (NHP) reported strong Q1 2026 results with normalized FFO doubling year-over-year to $0.26 per share, following its April 2026 IPO. The company is strategically shifting focus to senior housing, planning significant acquisitions and divestitures of outpatient medical facilities. NHP's stock saw a 2.05% premarket increase, reflecting investor confidence in its strategic direction and operational performance.
Ventyx Biosciences stock (US92276F1003): Acquired by Eli Lilly for $1.2B in January
Ventyx Biosciences, a clinical-stage biotech firm, was acquired by Eli Lilly and Company for approximately $1.2 billion in January 2026. This acquisition is set to bolster Lilly's oncology and immunology portfolios, aligning with the industry trend of large pharmaceutical companies expanding their pipelines through M&A activities. The deal highlights the value of innovative biotech companies focusing on precision immunology therapies and signifies ongoing consolidation in the sector.
